Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

While the FDA has yet to issue a warning for NAION, it is actively monitoring reports of the condition linked to GLP-1 drugs.

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

A BMJ guideline put patient risk into the equation for assessing the suitability of SGLT-2 inhibitors and GLP-1 receptor agonist drugs for type 2 diabetes. Their use in type 2 diabetes was only ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.

Biologics, including GLP-1 analogs and PCSK9 inhibitors, are advancing treatment options for metabolic syndrome components like type 2 diabetes and dyslipidemia. GLP-1 receptor agonists improve ...

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

In patients with type 2 diabetes (T2D), dual therapy with metformin and GLP-1 receptor agonists (RAs) was associated with a 39% lower risk for adiposity-related cancers and a 67% lower risk for ...

Patients with lupus and type 2 diabetes are predisposed to a disproportionate risk of atherosclerotic cardiovascular disease and chronic kidney disease. A study of this patient population showed that ...

Association persisted after removing patients with previous diagnosis of gastroesophageal reflux. (HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like ...